Bladder Cancer News and Research RSS Feed - Bladder Cancer News and Research

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis.
Clinical trial tests COXEN model in bladder cancer to find promising treatment

Clinical trial tests COXEN model in bladder cancer to find promising treatment

Imagine being able to match a cancer's genes to the best treatment. That's the promise of COXEN (CO eXpression ExtrapolatioN) - a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy. [More]
Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments. [More]
Comprehensive database collecting information about microRNAs, multiMiR

Comprehensive database collecting information about microRNAs, multiMiR

Your genes are blueprints for proteins, and molecules called microRNA can help to determine how often these genetic blueprints are manufactured into proteins. Researchers often ask what microRNA regulates a gene related to disease. [More]
9.3% of U.S. cancer survivors are current smokers, shows study

9.3% of U.S. cancer survivors are current smokers, shows study

Nine years after diagnosis, 9.3 percent of U.S. cancer survivors were current smokers and 83 percent of these individuals were daily smokers who averaged 14.7 cigarettes per day, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR). [More]
Global Urology Devices market estimated to grow at CAGR of 6.37% over 2013-2018

Global Urology Devices market estimated to grow at CAGR of 6.37% over 2013-2018

Research and Markets has announced the addition of the "Global Urology Devices Market 2014-2018" report to their offering. [More]
Study: Cohesin mutations are common in melanoma and bladder cancer

Study: Cohesin mutations are common in melanoma and bladder cancer

Massive sequencing of cancer genomes brings to light new genes every day that could be involved in the process of tumour formation. [More]
Research may lead to new assay to better diagnose bladder cancer in both dogs and humans

Research may lead to new assay to better diagnose bladder cancer in both dogs and humans

Veterinary researchers at Oregon State University have identified a unique group of proteins that indicate the presence of transitional cell carcinoma - the most common cause of bladder cancer - and may lead to a new assay which could better diagnose this disease in both dogs and humans. [More]
PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. [More]
New investigational immunotherapy benefits people with advanced urothelial bladder cancer

New investigational immunotherapy benefits people with advanced urothelial bladder cancer

A new investigational immunotherapy MPDL3280A has been shown to shrink tumours in 43% of people (13/30) who had previously been treated for advanced urothelial bladder cancer (UBC) with a specific type of tumour (PD-L1 positive). [More]
Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. [More]
Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology. [More]
Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center. [More]
Findings explain why women with bladder cancer are often diagnosed at later stage than men

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new Vanderbilt University study. [More]

Researcher receive 2014 Platinum Award for excellence during 2014 EAU Congress

Although Richard Sylvester officially retired in May 2012 after nearly 37 years at EORTC Headquarters, most of which were spent as the head of the Statistics Department, his scientific activities still keep him very busy. [More]
$15 million pledged for creation of Johns Hopkins Greenberg Bladder Cancer Institute

$15 million pledged for creation of Johns Hopkins Greenberg Bladder Cancer Institute

Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife Stephanie Cooper Greenberg have pledged a $15 million gift to create the Johns Hopkins Greenberg Bladder Cancer Institute. [More]
Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder. [More]
FDA accepts Merck's MK-3475 BLA for review

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. [More]
Nocturnal incontinence poses major burden after female bladder reconstruction

Nocturnal incontinence poses major burden after female bladder reconstruction

Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research. [More]
Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine. [More]

Bioniche Life Sciences sells Animal Health business to Vétoquinol

Vétoquinol and Bioniche Life Sciences Inc., today jointly announced the closing of the sale of Bioniche's Animal Health business to Vétoquinol. [More]